Table 1 MSC-derived exosomes in chemotherapy resistance
Exosome source | Cancer type | Method | Key cargo | Genes and pathways | Drug | Drug resistance | Ref |
|---|---|---|---|---|---|---|---|
hBMSCs | Gastric cancer | In vitro and in vivo |  | CaM-Ks/Raf/MEK/ERK | 5-FU | ↑ | [80] |
hBMSCs | Breast cancer | In vitro and in vivo | miR-222/223 |  | Carboplatin | ↑ | [22] |
hUMSCs | Breast cancer | In vitro |  | MMP-2 and ecto-5′-nucleotidase | Conventional chemotherapy | ↑ | [87] |
hBMSCs | Breast cancer | In vitro | miR-23b | MARCKS | DOX | ↑ | [88] |
hBMSCs | Breast cancer | In vitro | miR-21-5p | S100A6 | DOX | ↑ | [89] |
hBMSCs | Acute myeloid leukemia | In vitro |  | OCT4, NANOG and SOX2 | Ara-C | ↑ | [21] |
ADMSCs | Breast cancer | In vitro | miR-1236 | Wnt/β-Catenin | DDP | ↓ | [91] |
hUCMSCs | Ovarian cancer | In vitro | miR-146a | LAMC2/PI3K/Akt | DOX | ↓ | [92] |
hUCMSCs | Hepatocellular carcinoma | In vitro | miR-451a | ADAM10 | PTX | ↓ | [93] |